Anemia management in chronic kidney disease (Q39822858)

14 September 2017

1 reference

title

Anemia management in chronic kidney disease (English)

1 reference

14 September 2017

Steven Fishbane

1

1 reference

14 September 2017

Allen R Nissenson

series ordinal

2

1 reference

14 September 2017

publication date

1 August 2010

1 reference

Kidney International. Supplement

14 September 2017

published in

1 reference

14 September 2017

issue

117

1 reference

14 September 2017

page(s)

S3-9

1 reference

Anemia: an early complication of chronic renal insufficiency

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Anemia of end-stage renal disease (ESRD).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis Patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Influence of target hemoglobin in dialysis patients on morbidity and mortality.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Correction of anemia with epoetin alfa in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

What is needed to achieve a hemoglobin of 11.0-13.0 g/dl in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Ultrafiltration profiling and measurement of relative blood volume as strategies to reduce hemodialysis-related side effects

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Whole blood viscosity and arterial thrombotic events in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Relative Value of Inflammatory, Hemostatic, and Rheological Factors for Incident Myocardial Infarction and Stroke

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspective

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Effects of optimized heart failure therapy and anemia correction with epoetin beta on left ventricular mass in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Subcutaneous erythropoietin therapy: efficacy and economic implications

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Iron supplementation in renal anemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Influence of industry on renal guideline development

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Translating epoetin research into practice: the role of government and the use of scientific evidence

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Correction of Anemia — Payoffs and Problems

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

The normal hematocrit study--follow-up

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

The science of improvement

1 reference

https://api.crossref.org/works/10.1038%2FKI.2010.188

7 January 2021

Identifiers

DOI

10.1038/KI.2010.188

1 reference

Dimensions Publication ID

14 September 2017

1000875599

0 references

1 reference